Understanding the genetics and neurobiological pathways behind addiction (Review).

Alexandra Popescu, Maria Marian, Ana Miruna Drăgoi, Radu-Virgil Costea
Author Information
  1. Alexandra Popescu: Department of Psychiatry, 'Prof. Dr. Alex. Obregia' Clinical Hospital of Psychiatry, 041914 Bucharest, Romania.
  2. Maria Marian: Department of Psychiatry, 'Prof. Dr. Alex. Obregia' Clinical Hospital of Psychiatry, 041914 Bucharest, Romania.
  3. Ana Miruna Drăgoi: Department of Psychiatry, 'Prof. Dr. Alex. Obregia' Clinical Hospital of Psychiatry, 041914 Bucharest, Romania.
  4. Radu-Virgil Costea: Department of General Surgery, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Abstract

The hypothesis issued by modern medicine states that many diseases known to humans are genetically determined, influenced or not by environmental factors, which is applicable to most psychiatric disorders as well. This article focuses on two pending questions regarding addiction: Why do some individuals become addicted while others do not? along with Is it a learned behavior or is it genetically predefined? Recent data suggest that addiction is more than repeated exposure, it is the synchronicity between intrinsic factors (genotype, sex, age, preexisting addictive disorder, or other mental illness), extrinsic factors (childhood, level of education, socioeconomic status, social support, entourage, drug availability) and the nature of the addictive agent (pharmacokinetics, path of administration, psychoactive properties). The dopamine-mesolimbic motivation-reward-reinforcement cycle remains the most coherent physiological theory in addiction. While the common property of addictive substances is that they are dopamine-agonists, each class has individual mechanisms, pharmacokinetics and psychoactive potentials.

Keywords

References

  1. Neuron. 2011 Aug 25;71(4):656-70 [PMID: 21867882]
  2. Int J Obes (Lond). 2016 Mar;40 Suppl 1:S12-21 [PMID: 27001642]
  3. Biol Psychiatry. 2014 Jul 1;76(1):66-74 [PMID: 24143882]
  4. Alcohol Res Health. 2008;31(3):185-95 [PMID: 19881886]
  5. Addiction. 2020 Mar;115(3):482-492 [PMID: 31833150]
  6. Psychol Med. 2008 Sep;38(9):1351-60 [PMID: 18257941]
  7. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):134-46 [PMID: 25747926]
  8. Mol Psychiatry. 2018 Dec;23(12):2277-2286 [PMID: 29875475]
  9. J Clin Psychopharmacol. 2010 Aug;30(4):417-24 [PMID: 20631559]
  10. Pharmacol Rev. 2016 Apr;68(2):264-355 [PMID: 26841800]
  11. Eur J Neurosci. 2019 Aug;50(3):2164-2179 [PMID: 30256469]
  12. Compr Physiol. 2014 Oct;4(4):1339-68 [PMID: 25428846]
  13. Twin Res Hum Genet. 2016 Aug;19(4):297-305 [PMID: 27436053]
  14. Physiol Rev. 2015 Jul;95(3):853-951 [PMID: 26109341]
  15. Dev Psychobiol. 2010 Nov;52(7):638-50 [PMID: 20862707]
  16. Mol Neuropsychiatry. 2016 May;2(1):37-45 [PMID: 27606319]
  17. Neuropsychopharmacology. 2008 Jul;33(8):1779-97 [PMID: 17928814]
  18. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:188-93 [PMID: 26497079]
  19. J Exp Neurosci. 2018 May 31;12:1179069518779829 [PMID: 29899667]
  20. Int J Environ Res Public Health. 2018 Oct 22;15(10): [PMID: 30360407]
  21. Neuromolecular Med. 2004;5(1):85-108 [PMID: 15001815]
  22. Cell Transplant. 2019 Mar;28(3):233-238 [PMID: 30419763]
  23. Nat Neurosci. 2018 Sep;21(9):1161-1170 [PMID: 30150663]
  24. Pharmacol Biochem Behav. 2008 Jul;90(1):95-104 [PMID: 18440057]
  25. J Stud Alcohol Drugs. 2016 Sep;77(5):684-7 [PMID: 27588524]
  26. Am J Drug Alcohol Abuse. 2016 Mar;42(2):129-39 [PMID: 26809272]
  27. J Psychiatr Res. 2017 Aug;91:116-123 [PMID: 28334615]
  28. Chronobiol Int. 2019 Jan;36(1):122-134 [PMID: 30526093]
  29. Neuropsychopharmacology. 2012 Aug;37(9):2093-100 [PMID: 22549115]
  30. Neuropharmacology. 2011 Dec;61(7):1109-22 [PMID: 21459101]
  31. Exp Ther Med. 2020 Oct;20(4):3483-3487 [PMID: 32905000]
  32. Acta Endocrinol (Buchar). 2019 Jul-Sep;15(3):404-405 [PMID: 32010363]
  33. Aust Prescr. 2015 Oct;38(5):152-5 [PMID: 26648651]
  34. J Psychiatr Res. 2009 Apr;43(7):739-47 [PMID: 18996542]
  35. Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):422-7 [PMID: 26712009]
  36. Front Psychiatry. 2019 Jan 24;9:767 [PMID: 30733690]
  37. Psychopharmacology (Berl). 2017 May;234(9-10):1395-1418 [PMID: 28265714]
  38. Annu Rev Pharmacol Toxicol. 2009;49:57-71 [PMID: 18834313]
  39. Psychiatr Clin North Am. 2012 Jun;35(2):495-519 [PMID: 22640768]
  40. Eur Neuropsychopharmacol. 2016 Jan;26(1):55-64 [PMID: 26689328]
  41. Adv Pharmacol. 2010;58:373-96 [PMID: 20655489]
  42. Neuroscience. 2013 Jun 25;241:100-5 [PMID: 23531434]
  43. CNS Drugs. 2009 Nov;23(11):939-52 [PMID: 19845415]
  44. Psychopharmacology (Berl). 2016 May;233(10):1945-62 [PMID: 26873080]
  45. N Engl J Med. 2018 May 17;378(20):1888-1897 [PMID: 29768152]
  46. Mol Psychiatry. 2012 Jun;17(6):642-9 [PMID: 21747398]
  47. Nat Commun. 2017 May 30;8:15527 [PMID: 28556835]
  48. Br J Psychiatry. 1994 May;164(5):660-4 [PMID: 7921717]
  49. Int J Environ Res Public Health. 2010 Oct;7(10):3760-91 [PMID: 21139859]
  50. BMC Psychiatry. 2015 Apr 15;15:86 [PMID: 25886577]
  51. Acta Neuropsychiatr. 2018 Feb;30(1):43-57 [PMID: 27866486]
  52. Neuropsychopharmacology. 2012 Dec;37(13):2809-16 [PMID: 22948977]
  53. Hum Mol Genet. 2007 Jan 1;16(1):24-35 [PMID: 17158188]
  54. J Comp Physiol Psychol. 1954 Dec;47(6):419-27 [PMID: 13233369]
  55. Cell. 2015 Aug 13;162(4):712-25 [PMID: 26276628]
  56. CPQ Neurol Psychol. 2018;1(2): [PMID: 30957097]
  57. J Abnorm Psychol. 2007 Feb;116(1):213-8 [PMID: 17324032]
  58. Science. 1983 Aug 19;221(4612):773-5 [PMID: 6879176]
  59. Cochrane Database Syst Rev. 2018 Nov 26;11:CD012557 [PMID: 30484285]
  60. Rom J Morphol Embryol. 2020;61(1):25-32 [PMID: 32747892]
  61. CMAJ. 2001 Feb 6;164(3):397 [PMID: 11232151]
  62. Exp Neurol. 2004 May;187(1):47-57 [PMID: 15081587]
  63. Behav Neurol. 2015;2015:103969 [PMID: 25861156]
  64. J Syst Integr Neurosci. 2018 May 3;4: [PMID: 31750006]
  65. Curr Top Behav Neurosci. 2018;36:45-73 [PMID: 28677096]
  66. J Exp Anal Behav. 2005 Nov;84(3):667-81 [PMID: 16596985]
  67. Psychopharmacology (Berl). 2005 Aug;180(4):583-94 [PMID: 15834536]
  68. Med Care Res Rev. 2012 Apr;69(2):123-57 [PMID: 22203646]
  69. Eur J Neurosci. 2009 Jul;30(1):1-8 [PMID: 19508697]
  70. Adv Psychosom Med. 2011;30:22-60 [PMID: 21508625]
  71. Cold Spring Harb Perspect Med. 2013 Mar 01;3(3):a012047 [PMID: 23359110]
  72. Exp Ther Med. 2020 Jul;20(1):73-77 [PMID: 32508997]
  73. Physiol Rev. 2009 Oct;89(4):1379-412 [PMID: 19789384]
  74. Mol Neurobiol. 2015 Apr;51(2):696-717 [PMID: 24939695]
  75. Addict Sci Clin Pract. 2011 Jul;6(1):4-16 [PMID: 22003417]
  76. J Anal Toxicol. 2018 Jun 1;42(5):285-292 [PMID: 29462364]
  77. Neuropharmacology. 2011 Sep;61(3):421-32 [PMID: 21466815]
  78. Indian J Psychiatry. 2008 Apr;50(2):117-20 [PMID: 19742220]
  79. J Behav Addict. 2018 Sep 1;7(3):556-561 [PMID: 30010410]
  80. Mol Neurobiol. 2016 Jan;53(1):545-560 [PMID: 25502297]
  81. J Mol Neurosci. 2013 Mar;49(3):550-3 [PMID: 22740152]
  82. Handb Clin Neurol. 2014;125:477-97 [PMID: 25307591]
  83. Postepy Hig Med Dosw (Online). 2017 Mar 13;71(0):205-213 [PMID: 28345528]
  84. BMC Psychiatry. 2018 Dec 20;18(1):396 [PMID: 30572854]
  85. Neurotherapeutics. 2017 Jul;14(3):687-697 [PMID: 28324454]
  86. Pain. 2013 Apr;154(4):598-608 [PMID: 23398938]
  87. Subst Use Misuse. 2019;54(4):670-680 [PMID: 30663487]
  88. Neurosci Biobehav Rev. 2016 May;64:359-81 [PMID: 26987641]
  89. Drug Discov Today Dis Models. 2008 Winter;5(4):235-245 [PMID: 20582332]
  90. Lancet Psychiatry. 2016 Aug;3(8):760-773 [PMID: 27475769]
  91. Biol Psychol. 2010 Sep;85(1):33-7 [PMID: 20452395]
  92. Nat Rev Gastroenterol Hepatol. 2013 Aug;10(8):487-94 [PMID: 23712313]
  93. Am J Psychiatry. 2018 Mar 1;175(3):225-231 [PMID: 29241357]
  94. Pharmacol Ther. 2019 Mar;195:132-161 [PMID: 30347211]
  95. Physiol Behav. 2011 Jul 25;104(1):76-81 [PMID: 21549724]
  96. Curr Psychiatry Rep. 2018 Mar 5;20(2):8 [PMID: 29504045]
  97. Am J Drug Alcohol Abuse. 2010 Sep;36(5):268-76 [PMID: 20545602]
  98. Psychopharmacology (Berl). 2009 Sep;206(1):1-21 [PMID: 19547960]
  99. Int J Mol Sci. 2019 Sep 02;20(17): [PMID: 31480739]
  100. CNS Drugs. 2016 Aug;30(8):719-33 [PMID: 27401883]
  101. Front Pharmacol. 2014 Sep 02;5:204 [PMID: 25228881]

Word Cloud

Created with Highcharts 10.0.0addictionfactorsaddictivegeneticallylearnedbehaviorpharmacokineticspsychoactivegeneticshypothesisissuedmodernmedicinestatesmanydiseasesknownhumansdeterminedinfluencedenvironmentalapplicablepsychiatricdisorderswellarticlefocusestwopendingquestionsregardingaddiction:individualsbecomeaddictedothersnot?alongpredefined?Recentdatasuggestrepeatedexposuresynchronicityintrinsicgenotypesexagepreexistingdisordermentalillnessextrinsicchildhoodleveleducationsocioeconomicstatussocialsupportentouragedrugavailabilitynatureagentpathadministrationpropertiesdopamine-mesolimbicmotivation-reward-reinforcementcycleremainscoherentphysiologicaltheorycommonpropertysubstancesdopamine-agonistsclassindividualmechanismspotentialsUnderstandingneurobiologicalpathwaysbehindReviewdopamineepigeneticsrewardcircuit

Similar Articles

Cited By